Lv6
2520 积分 2022-11-23 加入
Mutual ATRaction: Assessing Synergy of Berzosertib with Sacituzumab Govitecan
6个月前
已完结
Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
6个月前
已完结
A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer
8个月前
已完结
Targeting the DNA Damage Response for Cancer Therapy
8个月前
已完结
The Trop-2-targeting antibody drug conjugate DB-1305 has higher antitumor activity and a potentially better safety profile compared with DS-1062
10个月前
已完结
The Trop-2-targeting antibody drug conjugate DB-1305 has higher antitumor activity and a potentially better safety profile compared with DS-1062
10个月前
已完结
补充材料 of BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
11个月前
已完结
[Consensus on the molecular residual disease testing in solid tumor]
11个月前
已完结
CCNE1Amplification as a Therapeutic Target
1年前
已完结
Antibody–drug conjugates: current status and future directions
1年前
已完结
皖公网安备34019202002308
